Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865182 | 0.83 | NAPRT (0.55) | NAPRTDAOKDM4EALDH1A1PARP1 | |
| SCHEMBL14829176 | 0.83 | NAPRT (0.41) | NAPRTDAOKDM4EALDH1A1PARP1 | |
| SCHEMBL8469600 | 0.81 | PDPK1 (0.43) | NAPRTDAOKDM4EALDH1A1PARP1 | |
| SCHEMBL19350248 | 0.80 | CXCR2 (0.39) | NAPRTDAOKDM4EALDH1A1PARP1 | |
| SCHEMBL754622 | 0.76 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3182033 | 0.74 | NAPRT (0.67) | NAPRTDAOKDM4EALDH1A1RAB9A | |
| SCHEMBL3657128 | 0.73 | — | — | |
| SCHEMBL5004910 | 0.73 | PBRM1 (0.39) | NAPRTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14540483 | 0.73 | — | — | |
| SCHEMBL765517 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | claimed |
| WO-2010114919-A2 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | STC.UNM (US) | 2010-10-07 | — | — | WO | claimed |
| EP-0120669-A2 | Hydroxypyridones, and their pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-10-03 | — | — | EP | disclosed |
| EP-0120670-A1 | Iron III complexes of hydroxypyridones, and their pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | NAPRT 2116/4885DAO 1912/4885KDM4E 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.